[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Soft Tissue Biologics (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)

June 2020 | | ID: S65B3B000109EN
GlobalData

US$ 7,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Soft Tissue Biologics (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)

SUMMARY

Soft Tissue Biologics (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within Orthopedic Devices therapeutic area.
The model discusses in detail the impact of COVID-19 on Soft Tissue Biologics market for the year 2020 and beyond. Orthopedic soft tissue biologics are widely used in procedures where tendon or ligament is torn or damaged in the human body. They are made from substances that are naturally found in the body and can be used in regeneration and repair of the musculoskeletal tissues.
Minimally invasive surgery and arthroscopy has helped in early intervention and treatment of multiple medical conditions and regenerative medicine has facilitated the in-growth, expansion and preservation of the normal tissue.
The orthopedic soft tissue biologics market is primarily driven by procedures performed for anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) reconstruction, rotator cuff repair, and Achilles tendon repair. Other medical conditions where soft tissue biologics are used include: Medial Collateral Ligament repair, Lateral Collateral Ligament repair, Medial Patellofemoral Ligament repair, Ulnar Collateral Ligament repair, flexor tendon and hip flexor repair.
Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are -
Currently marketed Soft Tissue Biologics and evolving competitive landscape -
  • Insightful review of the key industry trends.
  • Annualized total Soft Tissue Biologics market revenue by segment and market outlooks from 2015-2030.
  • Granular data on total procedures, units, average selling prices and market values by segment.
Global, Regional and Country level market specific insights -
  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Soft Tissue Biologics market.
  • Competitive dynamics insights and trends provided for Soft Tissue Biologics market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: ConMed Corporation, LifeNet Health Inc, RTI Surgical Inc, Allosource, Arthrex Inc, Smith & Nephew plc and Others
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

SCOPE

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
  • CMO executives who must have deep understanding of the Soft Tissue Biologics marketplace to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
REASONS TO BUY

The model will enable you to -
  • Understand the impact of COVID-19 on Soft Tissue Biologics market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Soft Tissue Biologics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Soft Tissue Biologics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Soft Tissue Biologics market from 2015-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


COMPANIES MENTIONED

ConMed Corporation
LifeNet Health Inc
RTI Surgical Inc
Allosource
Arthrex Inc
Smith & Nephew plc


More Publications